Inotiv, Inc. Announces Changes to its Board Composition
October 16 2023 - 8:00AM
Inotiv, Inc. (Nasdaq: NOTV), a leading contract
research organization, today announced the appointment of Terry
Coelho to its Board of Directors. Ms. Coelho is replacing Richard
A. Johnson PhD, who is leaving the Board as part of the Board’s
succession planning. Ms. Coelho was also appointed to serve as a
member of the Compensation Committee and the Audit Committee, and
as a member and the Chair of the Nominating/Corporate Governance
Committee of the Board.
Ms. Coelho is the CFO at Gamida Cell Ltd., a public, commercial
stage biotech company. Previously, Ms. Coelho was Executive Vice
President, CFO and Chief Business Development Officer of CinCor
Pharma, Inc., where she led the $190 million IPO in January 2022,
followed by a follow-on offering, prior to its sale to AstraZeneca
for approximately $1.8 billion. Her previous experience includes
serving as CFO of BioDelivery Sciences International, Balchem
Corporation and Diversey, the finance lead for Novartis’ oncology
hematology franchise and Global Head of Oncology Development
Finance at Novartis, as well as various positions of increasing
responsibility within Mars, Inc. Ms. Coelho is a member of the
boards of directors of First Wave Biopharma, Inc. and HOOKIPA
Pharma Inc..
Gregory C. Davis, Chairman of the Board, commented, “We are
delighted to welcome Terry as our newest director at this important
inflection point for Inotiv. She brings extensive experience to the
Board as a business leader and senior executive. With more than
fifteen years spent leading biopharmaceutical companies and major
divisions of multinational pharmaceutical companies, Terry is
uniquely suited to help drive Inotiv’s strategy to be a provider of
first choice to the pharmaceutical research and development
community. We look forward to the fresh perspectives and
contributions she will bring to Inotiv’s Board of Directors.”
“I want to thank Richard for his consistent and thoughtful
guidance throughout his tenure on the board at Inotiv,” noted
Robert Leasure, President and CEO. “Since joining the Board of
Directors in 2012, he has brought a broad perspective on scientific
matters that has been integral to the successful growth and
development of our company.”
About Inotiv
Inotiv, Inc. is a leading contract research
organization dedicated to providing nonclinical and analytical drug
discovery and development services and research models and related
products and services. The Company’s products and services focus on
bringing new drugs and medical devices through the discovery and
preclinical phases of development, all while increasing efficiency,
improving data, and reducing the cost of taking new drugs to
market. Inotiv is committed to supporting discovery and development
objectives as well as helping researchers realize the full
potential of their critical R&D projects, all while working
together to build a healthier and safer world. Further information
about Inotiv can be found here: https://www.inotivco.com/.
This release contains forward-looking statements
that are subject to risks and uncertainties including, but not
limited to, risks and uncertainties related to the impact of recent
events related to non-human primate matters on the Company’s
business, operations, results, financial condition, cash flows, and
assets, the Company’s ability to comply with covenants under its
credit agreement, Company’s ability to reduce its legal and third
party fees, changes in the market and demand for the Company’s
products and services, the development, marketing and sales of
products and services, changes in technology, industry and
regulatory standards, the timing of acquisitions and the successful
closing, integration and business and financial impact thereof,
governmental regulations, inspections and investigations, claims,
investigations and litigation against or involving the Company, its
business and/or its industry, the impact of site closures and
consolidations, expansion and related efforts, and various other
market and operating risks, including those detailed in the
Company's filings with the U.S. Securities and Exchange
Commission.
Company Contact |
|
Investor Relations |
Inotiv, Inc. |
|
LifeSci Advisors |
Beth A. Taylor, Chief Financial Officer |
|
Bob Yedid |
(765) 497-8381 |
|
(516) 428-8577 |
btaylor@inotivco.com |
|
bob@lifescieadvisors.com |
|
|
|
Inotiv (NASDAQ:NOTV)
Historical Stock Chart
From Apr 2024 to May 2024
Inotiv (NASDAQ:NOTV)
Historical Stock Chart
From May 2023 to May 2024